Ophthalmic Pharmacotherapy Dossier • CFP-US-LT-OPHTH-LATANOPROST-L2

Latanoprost 0.005% Ophthalmic Solution (Xalatan) Prostaglandin F2a Analogue

Clinical tonometric mechanisms, aqueous humor hydrodynamics, lacrimal immunomodulation, and verified outpatient pharmacy dispensation protocols.

Clinical Pharmacology & Mechanisms of Action

Isopropyl ester prodrug of prostaglandin F2α selective prostanoid FP receptor agonist. Increases the uveoscleral outflow of aqueous humor without significantly affecting trabecular outflow or aqueous production, achieving profound intraocular pressure (IOP) reduction in open-angle glaucoma.

Target Receptor / Outflow Pathway

Selective Prostanoid FP Receptor Agonism with Uveoscleral Extracellular Matrix Remodeling

Pharmacokinetic Onset & Tmax

3-4 hours (Initial IOP reduction), 8-12 hours (Peak hypotensive response)

Validated Clinical Endpoint

27-35% mean reduction in baseline intraocular pressure and preservation of visual field sensitivity

Evidence Hierarchy Tier

Tier-L2 (Blog Web2)

Recommended Administration & Application Regimen

Therapeutic application must strictly align with validated international ophthalmic guidelines for ocular hypertension, open-angle glaucoma, and keratoconjunctivitis sicca:

Standard Prescribing Protocol: One drop in the affected eye(s) once daily in the evening for optimal circadian IOP control

Ensure nasolacrimal occlusion for 2 minutes immediately following instillation to minimize systemic absorption and optimize localized intraocular bioavailability.

Verified Outpatient Dispensation Protocols

Legitimate patient access for Latanoprost 0.005% Ophthalmic Solution (Xalatan) Prostaglandin F2a Analogue via accredited international mail-order pharmacy distribution networks with strict cold-chain and sterility compliance.

Starting from $0.85 per bottle / pack

Access Accredited Pharmacy Portal

SSL 256-Bit Encrypted Transfer • Sterile GMP Packaging • Discreet Global Delivery

Safety, Contraindications & Clinical Precautions

Prior to prescribing Latanoprost 0.005% Ophthalmic Solution (Xalatan) Prostaglandin F2a Analogue, clinicians must evaluate history of ocular herpes simplex keratitis, uveitis, macular edema risk in aphakic eyes, and severe cardiovascular disease.

Prostaglandin analogues may cause gradual, permanent iris hyperpigmentation and periocular fat atrophy (prostaglandin-associated periorbitopathy).
Allow at least 5 to 10 minutes between instillation of different topical ophthalmic solutions to prevent washout of active ingredients.
Contact lenses must be removed prior to instillation of solutions containing benzalkonium chloride (BAK) and may be reinserted after 15 minutes.